These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 19038731)

  • 41. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA; Rivera MP
    Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    Pakkala S; Ramalingam SS
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
    J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
    Juergens R; Brahmer J
    Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
    Byrne BJ; Garst J
    Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
    Reck M; Kranich AL; Steinbach AK; Gatzemeier U
    Med Klin (Munich); 2005 Dec; 100(12):785-93. PubMed ID: 16453093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
    Herbst RS; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
    Takeda M; Nakagawa K
    Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
    Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
    Sridhar SS; Seymour L; Shepherd FA
    Lancet Oncol; 2003 Jul; 4(7):397-406. PubMed ID: 12850190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
    Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted therapies for advanced non-small cell lung cancer.
    Starakis I; Nikolakopoulos A; Mazokopakis EE
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
    Gridelli C; Maione P; Ferrara ML; Rossi A
    Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P; González AL; García-Palomo A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
    Natale RB
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
    Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
    Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.